EN DE
Watch Jinxin Fertility Group Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jinxin Fertility Group Ltd (1951) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Jinxin Fertility Group Ltd stock HK$2.14, price HK$2.30, that is 6.8% below the price, quality 45 out of 100. Rating: fairly valued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG5140J1013

JF Jinxin Fertility Group Ltd logo Thin data Nov 12, 2026

Jinxin Fertility Group Ltd

1951 · HK

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
1.6% dividend yield · Cash covered
Fair value HK$2.14 · Fairly valued 
Quality 45/100 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 5y +12.6 %/yr in CNY) 
Thin margins · 6.3% net margin (TTM) 
Mixed vs. peers (6/14) 
Profit last quarter 33% below a year ago. 
Changed on Oct 29: HK$1.73 → HK$2.14 
Narrow moat 32/100 · thin data
Thin data 
Watch Jinxin Fertility Group Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$18.54 HK$1.93 Fair Value HK$2.14 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range HK$1.93 – HK$18.54 · fair‑value band HK$1.02 – HK$3.75 · the HK$2.30 price screens above the HK$2.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Jinxin Fertility Group in your weekly email

Every Wednesday you see whether Jinxin Fertility Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally.

Show moreShow less

The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection.

It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services.

Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services.

Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant.

Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.

Stock analysis

Jinxin Fertility Group Ltd (1951) currently trades at HK$2.30, while our model-based Fair Value estimate is HK$2.14, so the stock looks roughly fairly valued today (gap 7.3%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$2.14 per share, and 3 of the 13 models we run sit above the HK$2.30 price.

Bear case: the Earnings-Based group reads lowest at HK$0.3100, and 10 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$1.02 (bear) to HK$3.75 (bull), the price of HK$2.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jinxin Fertility Group Ltd reported revenue of 2.6B CNY in FY2025 versus 1.8B CNY in FY2021, a compound +8.8%/yr. Reported net income was −951M CNY in FY2025.

Key figures

Market cap HK$6.1B (≈ $776M) Small · P/E ratio 28.4 · P/S ratio 2.08 · Dividend yield 1.6% · Net margin −36.8% · Return on equity 1.9% · Return on assets (EBIT) 2.5% (5-year average) · Operating margin 14.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −7%, 1951 screens richer than that median.

Fair Value models

Bear HK$1.02 Fair Value HK$2.14 Bull HK$3.75
Price HK$2.30 · Downside -6.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$1.07 HK$2.14 HK$4.50 75
Growth DCF HK$1.02 HK$2.17 HK$3.75 75
EPV HK$0.2200 HK$0.3100 HK$0.3900 73
All 13 models by family
DCF Models
FCF DCF HK$1.07 HK$2.14 HK$4.50 75
5Y Revenue Exit HK$0.6400 HK$1.43 HK$2.51 69
5Y EBITDA Exit HK$1.71 HK$3.78 HK$6.54 72
10Y Revenue Exit HK$0.7600 HK$1.54 HK$2.80 63
10Y EBITDA Exit HK$1.44 HK$3.18 HK$6.08 64
Earnings-Based
EPV HK$0.2200 HK$0.3100 HK$0.3900 73
Multiples
EV/EBIT HK$0.2200 HK$0.6200 HK$1.01 61
EV/EBITDA HK$1.71 HK$2.60 HK$3.49 66
EV/Revenue n/a HK$0.2400 HK$0.6100 50
Asset-Based
NCAV (Graham) HK$0.1200 HK$0.1700 HK$0.2500 54
Growth DCF
Growth DCF HK$1.02 HK$2.17 HK$3.75 75
Rev-Margin DCF HK$0.6400 HK$1.41 HK$2.47 69
Economic Profit
ROIC Compounder HK$0.2200 HK$0.3100 HK$0.3900 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 43
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.7% (2020) → 7.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +19.3% a year for the price and +6.1% for the forecasts.
Forecast 2026 (sales)+10.5%
Forecast 2027 (sales)+8.4%
Projected 2028 (sales)+7.6%
Projected 2029 (sales)+6.8%
Projected 2030 (sales)+6.0%

Watch 1951, get fair value alerts →

Compare Jinxin Fertility Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −6.8% · Below median
Profitability
Return on equity (12 months) 1.9% · Below median
Return on assets −6.8% · Bottom 25%
Net margin (12 months) 6.3% · Above median
Operating margin (12 months) 14.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 6.6% · Above median
Dividend yield (12 months) 1.6% · Below median
Balance sheet
Debt / equity 0.20× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 28.4× · Pricier than median
P/B 0.57× · Cheapest 25%
P/S (12 months) 1.89× · Pricier than median
Price / free cash flow (fiscal year) 23.7× · Pricier than median
EV/EBITDA 10.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 34
FUTURE (revenue growth)33 · sector 31
PAST (return on equity)7 · sector 31
HEALTH (low debt)90 · sector 90
DIVIDEND (yield)32 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 1951
DaVita Inc DVA $174.56 $218.90 +25% vs 1951
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 1951
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 1951
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 1951
The Ensign Group ENSG $188.41 $140.09 −26% vs 1951
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 1951
Fresenius SE FRE €53.62 €34.77 −35% vs 1951
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 1951
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 1951

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jinxin Fertility Group Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jinxin Fertility Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1951

Frequently asked questions

Is Jinxin Fertility Group Ltd (1951) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of HK$2.14 versus a price of HK$2.30, about 7% lower (fairly valued).
What is the fair value of 1951?
Our model-based fair value for Jinxin Fertility Group Ltd is HK$2.14 (as of Nov 12, 2026), built from audited fundamentals. The current price: HK$2.30.
What is the quality score of 1951?
Jinxin Fertility Group Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jinxin Fertility Group Ltd (1951)?
Our model-based price target is the fair value of HK$2.14 (as of Nov 12, 2026) from 13 valuation models. Cautious scenario HK$1.02, optimistic scenario HK$3.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Jinxin Fertility Group Ltd stock forecast for 2026?
Our models put fair value at HK$2.14, about 7% lower versus a price of HK$2.30 (fairly valued). Cautious scenario HK$1.02, optimistic scenario HK$3.75. The calculation is refreshed regularly with new filings.
What is the revenue of Jinxin Fertility Group Ltd (1951)?
Jinxin Fertility Group Ltd reported trailing-twelve-month revenue of about 2.7B CNY (latest available figure, as of Nov 12, 2026).
Does Jinxin Fertility Group Ltd pay a dividend?
Jinxin Fertility Group Ltd currently shows a dividend yield of 1.61% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Jinxin Fertility Group Ltd (1951) and when is the ex-dividend date?
Jinxin Fertility Group Ltd pays a dividend of HK$0.037 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Jun 29, 2026. Free cash flow covers the dividend 1.46 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Jinxin Fertility Group Ltd (1951)?
For today's price to be fair in a discounted-cash-flow model, Jinxin Fertility Group Ltd would have to grow free cash flow by 21.3 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 12.6 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of 1951 use?
Our models discount Jinxin Fertility Group Ltd at 11.1 %: a base by market capitalisation (small), damped by beta 0.77, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jinxin Fertility Group Ltd that is +21.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Jinxin Fertility Group Ltd (1951) delivered so far?
Over the past 5 years revenue at Jinxin Fertility Group Ltd grew 12.6 % a year. The price currently implies free-cash-flow growth of +21.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jinxin Fertility Group Ltd (1951) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Jinxin Fertility Group Ltd (+21.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jinxin Fertility Group Ltd (1951)?
The free-cash-flow yield on the price is 4.22 %: that much free cash flow Jinxin Fertility Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jinxin Fertility Group Ltd (1951)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jinxin Fertility Group Ltd it is HK$2.14 per share (as of Nov 12, 2026), against a price of HK$2.30. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Jinxin Fertility Group Ltd stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 1951 trades above its calculated fair value: price HK$2.30, fair value HK$2.14, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1951?
No. The price is what the market pays today (HK$2.30); the fair value is what the company's own numbers justify (HK$2.14). For Jinxin Fertility Group Ltd the two are HK$0.1550 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jinxin Fertility Group Ltd worth?
The market values Jinxin Fertility Group Ltd at about HK$6.1B (market capitalisation, as of Nov 12, 2026). Per share that is HK$2.30; our models calculate a fair value of HK$2.14 per share.
What do the bullish and bearish scenarios say about 1951?
Our models span a range for Jinxin Fertility Group Ltd: cautious scenario HK$1.02, base HK$2.14, optimistic HK$3.75 per share (as of Nov 12, 2026, price HK$2.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1951?
Jinxin Fertility Group Ltd trades at a price-to-earnings ratio of 28.4 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.14 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 24.4 (the reported result was a loss). Other multiples: P/B 0.6, P/S 1.9, EV/EBITDA 10.6.
How solid is the balance sheet of Jinxin Fertility Group Ltd (1951)?
Balance-sheet figures for Jinxin Fertility Group Ltd (as of Nov 12, 2026): return on equity 1.9%, debt of 0.20 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 1951 from its 52-week high?
Jinxin Fertility Group Ltd trades at HK$2.30, about 9% below its 52-week high of HK$2.54 and 19% above the low of HK$1.93 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.14 is for.
Which stocks are comparable to Jinxin Fertility Group Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jinxin Fertility Group Ltd stock attractive at the current price?
The data as of Nov 12, 2026: price HK$2.30, calculated fair value HK$2.14 (−7%), Quality Score 45/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1951 calculated?
We run Jinxin Fertility Group Ltd through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of HK$2.14 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Jinxin Fertility Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jinxin Fertility Group Ltd (1951)?
The closing price on Nov 13, 2026 was HK$2.30. Our model-based fair value is HK$2.14, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jinxin Fertility Group Ltd right now?
The model range is unusually wide (HK$1.02 to HK$3.75). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Jinxin Fertility Group Ltd

How large is the market capitalisation of Jinxin Fertility Group Ltd (1951)?
The market capitalisation of Jinxin Fertility Group Ltd is HK$6.1B (≈ $776M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jinxin Fertility Group Ltd (1951)?
The price-to-sales ratio of Jinxin Fertility Group Ltd is 2.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Jinxin Fertility Group Ltd (1951)?
The dividend yield of Jinxin Fertility Group Ltd is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jinxin Fertility Group Ltd (1951)?
The net margin of Jinxin Fertility Group Ltd is −36.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jinxin Fertility Group Ltd (1951)?
The return on equity (ROE) of Jinxin Fertility Group Ltd is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jinxin Fertility Group Ltd (1951)?
On an EBIT basis the return on assets of Jinxin Fertility Group Ltd is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jinxin Fertility Group Ltd (1951)?
The operating margin of Jinxin Fertility Group Ltd is 14.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jinxin Fertility Group Ltd (1951)?
Revenue at Jinxin Fertility Group Ltd is growing 6.6% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jinxin Fertility Group Ltd (1951)?
Earnings per share at Jinxin Fertility Group Ltd are down 32.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jinxin Fertility Group Ltd (1951) carry?
The net debt of Jinxin Fertility Group Ltd is 2.1B CNY (fiscal year 2025, ≈ 9.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jinxin Fertility Group Ltd in the live analysis

One click puts Jinxin Fertility Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.